This hypothesis is suggested by the observed amelioration of mitochondrial dysfunctions typical of patients with Alzheimer’s disease upon administration of levetiracetam, the drug known to interact specifically with SV2A. This evidence concerns the gene SV2A and early-onset autosomal dominant Alzheimer disease.